stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Revenue
BeOne Medicines Ltd. - Sponsored ADR's revenue for fiscal 2025 was $5.3B, up 40.2% from $3.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $6.6B. Over the past ten years it has ranged from $1.1M (fiscal 2016) to $5.3B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. BeOne Medicines Ltd. - Sponsored ADR ranks 3rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $5.3B | 40.23% |
| FY2024 | $3.8B | 54.96% |
| FY2023 | $2.5B | 73.65% |
| FY2022 | $1.4B | 20.37% |
| FY2021 | $1.2B | 280.83% |
| FY2020 | $308.9M | (27.87%) |
| FY2019 | $428.2M | 116.03% |
| FY2018 | $198.2M | (16.85%) |
| FY2017 | $238.4M | 22,179.16% |
| FY2016 | $1.1M | (87.86%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.9B | 10.83% |
| Jun 2026 | $1.7B | 12.66% |
| Mar 2026 | $1.5B | 1.02% |
| Dec 2025 | $1.5B | 6.08% |
| 40 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR | $6.6B |
| INCY Incyte Corporation compare | $6.0B |
| ARGX argenex SE compare | $5.9B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| RPRX Royalty Pharma PLC compare | $2.6B |
| INSM Insmed, Inc. compare | $1.5B |
| RVMD Revolution Medicines, Inc. compare | $209.1M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ONC
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement